OrbusNeich Named “Health Partnership Awards 2023 – Outstanding Interventional Instrument Manufacturer”

(Hong Kong, 21 September 2023) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, has earned the title of “Outstanding Interventional Instrument Manufacturer” at the “Health Partnership Awards 2023” organized by well-known Hong Kong media ET Net, recognizing it for effectively improving the quality of life of patients with its innovative and comprehensive endovascular and structural heart interventional solutions, and supporting and contributing to public health services in the past year.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Our vision is to help save lives of patients suffering from vascular diseases worldwide with pioneering technologies, helping improve their quality of life. We value innovation and hold a total of more than 210 granted patents and published patent applications globally. Patients in over 70 countries and regions have benefited from our advanced and diverse PCI, PTA and structural heart interventional products. We are deeply honored by the recognition of our past efforts, and looking ahead, we remain committed to leveraging our expertise to lead innovation of medical devices. By doing so, we aim to more effectively address the needs of patients and contribute to building a healthier future.”

ET Net, a Hong Kong financial information platform, has organized the “Health Partnership Awards” for the fourth year in a row, aiming to raise public awareness of and care about healthy living and quality wealth management, as well as honor enterprises that excelled in contributing to medical and healthcare development, relevant services and promotion of physical and mental health among consumers in the past year.

Mr. Jason Chen, Executive Director and Chief Financial Officer of OrbusNeich, receives the “Health Partnership Awards 2023”.

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also the only PCI balloon manufacturer headquartered in China that ranked among the top six players in all major overseas PCI balloon markets including Japan (No. 2), Europe (No. 4), and the U.S. (No. 6) in terms of PCI balloon sales volume in 2021, according to a CIC report. In addition, it ranked No. 3 in Japan and No. 4 in the U.S. in terms of PTA balloon sales volume in 2021. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease. As of June 30 2023, OrbusNeich has more than 210 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.